Related Experiment Video

Updated: May 8, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing

Ana Podolski-Renić1, Milka Jadranin, Tijana Stanković

  • 1Department of Neurobiology, Institute for Biological Research, University of Belgrade, Bulevar Despota Stefana 142, Belgrade, Serbia.

Cancer Chemotherapy and Pharmacology
|August 13, 2013
PubMed
Abstract

Insights

Multi-drug resistance (MDR) in cancer cells leads to genetic changes like chromosomal alterations and P-glycoprotein (P-gp) overexpression. These MDR models are crucial for testing new anticancer drugs and identifying potential prognostic markers.

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Genetics

Background:

  • Multi-drug resistance (MDR) presents a significant challenge in effective cancer therapy.
  • In vitro models are essential for studying phenotypic changes induced by cytotoxic agents and for preclinical drug evaluation.

Purpose of the Study:

  • To investigate chromosomal, numerical, and structural changes in multi-drug resistant (MDR) cancer cell lines.
  • To analyze alterations in p53 and PTEN, and mdr1 gene single nucleotide polymorphisms (SNPs) and P-glycoprotein (P-gp) expression.
  • To evaluate the impact of these molecular changes on the efficacy of novel anticancer drugs.

Main Methods:

  • Analysis of cytogenetic changes, p53 and PTEN status, mdr1 gene SNPs, and P-gp expression in three human MDR cancer cell lines (NCI-H460/R, DLD1-TxR, U87-TxR).
  • Assessment of anticancer activities and MDR reversal potential of an Akt inhibitor (GSK690693), a Ras inhibitor (Tipifarnib), and two P-gp inhibitors.
  • Evaluation of drug responses based on cell type, MDR phenotype, mdr1 SNP presence, and tumor suppressor alterations.

Main Results:

  • Development of MDR was associated with polyploidy reduction (U87-TxR), 6q loss (all lines), p53 inactivation (U87-TxR), and PTEN inactivation (DLD1-TxR).
  • Overexpression of P-gp was observed in all MDR cell lines.
  • Tipifarnib and jatrophane diterpenoids demonstrated significant MDR reversal, sensitizing cancer cells to paclitaxel, with varying effects influenced by molecular characteristics.

Conclusions:

  • Acquired molecular and cytogenetic characteristics in MDR cancer cells may serve as potential clinical prognostic markers.
  • These characterized MDR cell lines provide a valuable platform for the preclinical assessment of novel anticancer agents.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...